The trend: Physicians are ramping up use of AI for pharma-related queries on medications, treatments, and drug interactions. But usage of AI trails search, according to a new Bain & Company. report. The big takeaway: Doctors trust search engines over AI for drug information—for now. The convergence of the two tools via AI Overviews on Google could lead to declining confidence in search results. The winner in securing physician trust could be clinical-specific AI tools like the widely used UptoDate or the emerging OpenEvidence, which brands itself as a ChatGPT for doctors.

GenAI is changing pharma marketing from content creation to pharmacovigilance. Brand marketers and agencies are moving from experimentation to broad adoption of AI assistance and more efficient, effective, and relevant consumer communications.

The trend: Consumer perception of healthcare providers worsens when they find out the doctor uses AI, according to research recently published in JAMA Network. Our take: Healthcare is inherently emotional, and many consumers might be under the impression that their doctor is using AI as a shortcut. In reality, the opposite might be true. Physicians use AI to make them more efficient and free them up to spend extra time with patients. But language and details matter, and providers and marketers must ensure this is reflected in their messaging.

The trend: Consumers generally find that AI-generated responses to their online health queries are only somewhat reliable, according to a new survey from the Annenberg Public Policy Center (APPC) of the University of Pennsylvania. Our take: As Google’s AI gets smarter, healthcare and pharma websites will lose search traffic. Google is in a race with OpenAI and other tech players to make its AI more intelligent and improve users’ search experiences. Other consumers will conduct more health queries on platforms like ChatGPT. Brands and publishers must optimize content for AI rather than for search, but they should also be developing strategies to connect more with consumers on non-search channels such as social media and CTV.

The news: Illinois passed a law banning AI therapy, becoming the first state to outlaw the technology for mental health advising. Therapists in the state can still use AI for administrative tasks like transcription and note taking, but not for diagnoses or treatment decisions. Our take: Healthcare providers need to balance the need for AI mental health chatbots with the potential for misuse. Look for digital health companies using tested science and research to develop AI therapy chatbots, transparent practices, and safeguards for flagging problems.

The trend: Investments in AI-powered digital health startups drove an increase in total VC funding for the sector throughout the first half of 2025, according to a recent Rock Health report. The big takeaway: Making AI an essential element of your digital health platform isn’t a differentiating factor anymore—it’s a requirement to draw investor interest and customer adoption. To stand out, healthcare AI players and their marketers should demonstrate the real-world impact of their tech through published research and case studies. And they must be careful not to overstate their AI capabilities, as doing so will drive potential and current customers to a competitor’s solution.

The news: Merck is teaming with McKinsey for a generative AI (genAI) program that streamlines clinical study reports (CSRs). The takeaway: GenAI is ideal for time-intensive precise medical writing and frees content creators for oversight and strategic tasks. While Merck and some others are already using it for regulatory filings, those who stall or keep their pilots in the experimentation phase risk losing valuable time-to-market advantages.

The trend: Few consumers use AI tools for the health and wellness activities they participate in, according to a recent survey from Menlo Ventures and Morning Consult of 5,031 U.S. adults in April 2025. The big takeaway: Consumers are right on the cusp of using AI as a health information tool. AI tools are getting smarter, but can still be unreliable—one faulty response to a query about a person’s symptoms or health condition can turn a user off for good. AI platforms must train their models on credible medical sources and collaborate with clinicians to review outputs for accuracy.

The news: A Microsoft AI pilot study showed a fourfold improvement in diagnostics compared with a panel of real doctors, but researchers acknowledged the continued need for human expertise. The takeaway: It’s evident AI is not a replacement for doctors, but it is a tool they should start adopting. There’s a window of opportunity for doctors and healthcare systems to grab a first-mover advantage by presenting AI as a co-pilot and a value-add that leads to more accurate diagnoses and more time spent with patients.

The news: Consumers who are more familiar with AI are also more likely to mistrust an AI-assisted diagnosis from their doctor, per a recently published Journal of Medical Internet Research survey. Our take: Physicians and healthcare marketers can’t assume people who are familiar with AI will be more comfortable with AI uses in healthcare. Marketers need to talk about AI as a tool with many positive effects like freeing doctors for longer personal interactions and resulting in fewer mistakes.

The data: Physicians are more bullish on AI in healthcare than patients. Our take: Doctors are still figuring out AI themselves—but they can’t lose sight of how important it is to keep patients informed. They’ll need to get patient consent for use cases such as transcribing visits, and should opt out of using AI if their patients aren’t comfortable with it.

The news: Novo Nordisk is partnering with AI drug discovery company Deep Apple Therapeutics to discover and develop new cardiometabolic drugs, including for obesity. The takeaway: Novo is not the biggest loser in the GLP-1 weight loss category, but it’s trailing Lilly in drug effectiveness, market value, and more importantly public perception. It’s critical for Novo to come up with new and better weight loss drugs—hence the deal with Deep Apple—but also polish its brand with consumers. A new CEO and new marketing direction could garner Novo some much-needed cachet.

US smart wearable users will surge past 100 million by 2025 as AI capabilities drive adoption. Generational preferences, device convergence, and rising form factors like smart glasses and rings will reshape the market through 2028.

The trend: GenAI tools like ChatGPT are providing fewer disclaimers that chatbots are not a substitute for professional medical advice, according to a recent study cited in MIT Technology Review. Our take: Tech players must prioritize user safety—not winning the AI race. Health warnings should be standard, and marketers will need to scale back claims that AI accuracy surpasses physicians’.

The news: GenAI models can easily be influenced to perpetuate false health facts when they’re fed made-up medical terms and information, per a new Mount Sinai research published in Nature last week. Our take: As more consumers rely on open GPT models for health answers, misinformation and intentional disinformation pose growing risks to both personal and public health. There’s an opportunity for healthcare and pharma marketers to step up science-based AI marketing and communications, such as Pfizer’s custom genAI medical query tool Health Answers that sources answers from medical journals and peer-reviewed research.

The news: Medical AI startup OpenEvidence inked a multi-year agreement with JAMA Network that gives the company access to full-text content from the American Medical Association’s 13 medical journals. Our take: OpenEvidence is competing with Wolters Kluwer’s UptoDate medical information tool, which is used by a few million clinicians worldwide and has recently integrated its own AI search capabilities. One big difference between the products is that OpenEvidence is free for doctors and generates revenue through advertising. Meanwhile, UptoDate does not provide advertising opportunities. We think that OpenEvidence’s internal AI prowess could give it the leg up as long as its in-platform advertising doesn’t turn off doctors too much.

The news: Here’s a look back at the most popular stories from January through June 2025. The final word: Gen Z’s healthcare attitudes, social health influencers, marketing strategies, and how patients use AI drew the most attention from our audience.

The news: Pharma advertisers spent more than $10 billion on prescription drug ads last year, with the top 10 drug brands accounting for $3.3 billion last year, per Fierce Pharma’s report based on MediaRadar data. Our take: As pharma marketers shift drug ad budgets from TV to more digital channels, they’ll have to shift thinking from spendy brand awareness to more nuanced messaging. Social media edutainment, paid AI search ads, and partnering with doctor and patient influencers can reach more relevant consumers and deliver higher ROI.

Google’s AI Overviews lead to fewer clicks on healthcare search results: An industry that heavily relies on search must optimize for visibility in AI Overviews while closely monitoring how AI changes consumer search behaviors.

The trend: Healthcare advertising motivates consumers to go online to do more research, or talk to a medical professional—but the majority of people have privacy concerns about personalized ads. Our take: Healthcare marketers are eager to use AI and targeting technology to make one-to-one connections with consumers. And it’s true that personalized ads can be more useful for people. However, marketers need to use transparent labeling, use conspicuous ad tags on social media, and preface targeted emails with explanations about why they’re being sent.

The news: Prescription drug approval timelines will shrink under an FDA pilot program that will reduce the approval timelines from a typical 10 months to just 1 to 2 months. Our take: Speedier reviews and new AI programs for drug developers are good ideas, but pharma companies should remember the COVID-19 vaccines speed-to-market backlash and weigh the time benefit against whether their drugs will gain trust with physicians and patients.

The news: Oura is partnering with Maven Clinic to integrate smart ring data with providers’ care and treatment plans. Our take: We think it will take a while for providers to incorporate device data into the decisions they make for patients, which are typically based on clinical research studies and medical literature. Oura shouldn’t bet too heavily on securing doctors’ trust, and instead home in on the recent advancements it’s making on using AI to drive a better consumer experience.